Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
: Our findings indicate that a neuronal protein aggregate clearance mechanism induced by ultrasound-mediated blood-brain barrier opening operates for tau, further supporting the potential of low-intensity ultrasound to treat neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Beclin 1 network regulates autophagy and apoptosis
Kang, R., Zeh, H. J., Lotze, M. T., & Tang, D. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.191 · Cited by 2,485 · cited 1×
“We observed a significant reduction of mTOR activity (p-mTOR/mTOR) in the SUS-treated mice as compared to the sham group (Figure 3D, E) We also investigated the levels of beclin 1, the mammalian ortholog of yeast Atg6, which plays a role in autophagosomal nucleation [33] and found that it was significantly increased i…”
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“the additional accumulation of amyloid-β aggregates as extracellular plaques, with tau forming neurofibrillary tangles (NFTs) [2, 3].”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Monitoring and Measuring Autophagy
Yoshii, S. R., & Mizushima, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091865 · Cited by 1,107 · cited 1×
“We next probed p62 as a marker for autophagic flux [35], given that this protein acts as a receptor which directly binds to LC3 and is selectively degraded by autophagy [36].”
BackgroundBlood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · cited 1×
“Hyperphosphorylation of tau at specific serine and threonine residues has been implicated in tau aggregation, the spread of pathology and neurodegeneration in Alzheimer’s disease [29].”
BackgroundArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model
Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · cited 5×
“for microglia in the phagocytosis of amyloid-β plaques [21, 31].”
BackgroundResultInfluentialSelf-citationStimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy
Schaeffer, V., Lavenir, I., Ozcelik, S., Tolnay, M., Winkler, D. T., & Goedert, M. (2012) · Brain · doi:10.1093/brain/aws143 · Cited by 343 · cited 2×
“These results further add to the claim that the induction of autophagy, achieved by either pharmacological interventions using methylene blue, trehalose or rapamycin [25, 44, 45], or by a non-pharmacological approach such as SUS, can reduce tau hyperphosphorylation, leading to functional improvements.”
BackgroundJordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326 · cited 2×
“amyloid-β pathology in a range of mouse models [19, 21].”
BackgroundLi, X., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04833.x · Cited by 324 · cited 1×
“mTOR is a negative regulator of autophagy and has been found to be increased in Alzheimer’s disease [43], with associated changes in its downstream substrates suggesting a loss of protein translational control.”
BackgroundCongdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297 · cited 1×
“These results further add to the claim that the induction of autophagy, achieved by either pharmacological interventions using methylene blue, trehalose or rapamycin [25, 44, 45], or by a non-pharmacological approach such as SUS, can reduce tau hyperphosphorylation, leading to functional improvements.”
BackgroundBurgess, A., Dubey, S., Yeung, S., Hough, O., Eterman, N., Aubert, I., & Hynynen, K. (2014) · Radiology · doi:10.1148/radiol.14140245 · Cited by 286 · cited 1×
“Another study reported that bilaterally sonicating the hippocampus without administering any antibodies reduced amyloid plaque pathology and restored spatial working memory [20].”
Backgroundvan Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Self-citationTau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · cited 2×
“Although recent clinical trials are targeting the underlying biology of these disorders [8], a major challenge is the limited bioavailability of antibodies and other therapeutic agents in the brain, due to their incomplete passage across the blood-brain barrier (BBB) [9].”
BackgroundSelf-citationRapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226
Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · cited 3×
“In a previous study, we showed that just four ultrasound treatments to deliver a 2N tau isoform-specific antibody fragment reduced anxiety-like behavior and tau hyperphosphorylation in P301L tau-expressing pR5 mice when compared to a treatment with the antibody fragment alone [22].”
BackgroundMethodInfluentialSelf-citationTau physiology and pathomechanisms in frontotemporal lobar degeneration
Bodea, L., Eckert, A., Ittner, L. M., Piguet, O., & Götz, J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13600 · Cited by 104 · cited 1×
“Under physiological conditions, tau is an unfolded and highly soluble protein that is enriched in the axon [4].”
BackgroundSelf-citationNew classification of tauopathies
Höglinger, G. U., Respondek, G., & Kovacs, G. G. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.07.001 · Cited by 57 · cited 1×
“Motor functions are important as the clinical spectrum of tauopathies includes not only syndromes with cognitive dysfunction, but also those with primary motor symptoms, including parkinsonism [23].”
Background
Cited by
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
Self-citationUltrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery
Kooiman, K., Roovers, S., Langeveld, S. A. G., Kleven, R. T., Dewitte, H., O'Reilly, M. A., Escoffre, J.-M., Bouakaz, A., Verweij, M. D., Hynynen, K., et al. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.01.002 · Cited by 359
Lin, X., Liu, S., Zhang, X., Zhu, R., Chen, S., Chen, X., Song, J., & Yang, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201912768 · Cited by 335
Leinenga, G., Koh, W. K., & Götz, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00809-4 · Cited by 97
Self-citationEpelbaum, S., Burgos, N., Canney, M., Matthews, D., Houot, M., Santin, M. D., Desseaux, C., Bouchoux, G., Stroer, S., Martin, C., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00981-1 · Cited by 72
Metadata
- Authors
- Pandit, R., Leinenga, G., & Götz, J.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 13
- Pages
- 3754-3767
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2949834798
- Cited by
- 114
- References
- 21
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.